Table 1.
Therapy types included in the survey, each on a separate page. Therapies A–R were explicitly asked for, while S–U and V–X were included as complement
| Annotation | Therapy type |
|---|---|
| A | 131I-NaI for benign thyroid diseases |
| B | 131I-NaI for thyroid remnant ablation of adults |
| C | 131I-NaI for thyroid remnant ablation of children and young adults |
| D | 131I-NaI for thyroid cancer therapy for adults |
| E | 131I-NaI for thyroid cancer therapy for children and young adults |
| F | 131I-mIBG for neuroblastoma |
| G | 131I-mIBG for adult neuroendocrine tumors |
| H | 177Lu-somatostatin analogues for neuroendocrine tumors |
| I | 90Y-somatostatin analogues for neuroendocrine tumors |
| J | 177Lu-PSMA therapy of castration resistant prostate cancer |
| K | 90Y resin microspheres (SIR-Spheres®) for intra-arterial treatments in the liver |
| L | 90Y glass microspheres (TheraSphere®) for intra-arterial treatments in the liver |
| M | Radiation synovectomy using 90Y-, 186Re-, or 169Er-colloids |
| N | 153Sm-EDTMP (Quadramet®) for bone metastases |
| O | 89SrCl2 (Metastron®) for bone metastases |
| P | 223RaCl2 (Xofigo®) for bone metastases |
| Q | 32P sodium-phosphate (Na3 32PO4) for myeloproliferative disease |
| R | 90Y-ibritumomab-tiuxetan (Zevalin®) for B-cell lymphoma |
| S–U | Therapy using alpha emitting radionuclides other than 223Ra |
| V–X | Therapy using other radiopharmaceutical |